Moderna, Inc. (MRNA)

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

• 年度报告（10-K）

  对公司业务、财务业绩和风险的年度概述。

  提交日期：2026-02-20

  查看文件

• 季度报告（10-Q）

  最近三个月财务表现的最新情况。

  提交日期：2026-07-31

  查看文件

• 临时报告（8-K）

  关于重大事件（如管理层变动或重要公告）的通知。

  提交日期：2026-09-30

  查看文件

• 1d agoNEGATIVE
  Azioni Moderna -6% nel premarket: ecco perché

  Moderna shares tumbled nearly 6% in pre-market trading following a downgrade from Citi, which moved the biotech firm from 'Hold' to 'Sell'. Citi cited concerns that the recent valuation is difficult to justify, despite raising its price target to $80 from $60. The new target remains significantly below Tuesday's closing price of $203.46. This downgrade follows a near seven-fold increase in Moderna's stock this year, partly fueled by positive late-stage trial results for its personalized cancer vaccine candidate, intismeran autogene. Citi's revised assumptions on sales and operating expenses underpin the downgrade.

• 10d agoPOSITIVE
  Moderna will reveal the data for its mRNA cancer vaccine next month. Here’s why it matters.

  Moderna is set to unveil data for its mRNA cancer vaccine next month, a development keenly awaited by analysts and medical professionals. The key focus will be on the efficacy of the personalized treatment, which aims to tailor vaccines to individual tumor mutations. Positive results could validate Moderna's platform beyond infectious diseases and open a significant new revenue stream. Investors will be scrutinizing the data for robust clinical outcomes and potential market penetration, which could significantly impact the company's valuation and future growth prospects in the oncology space.

• 14d agoPOSITIVE
  Moderna +8%: il rally del vaccino anti-cancro può proseguire?

  Moderna Inc. shares surged 8% as investors reacted to positive Phase 3 trial results for its personalized mRNA cancer vaccine, intisemran autogene, developed with Merck. The treatment demonstrated a significant reduction in the risk of melanoma recurrence or death when combined with Merck's Keytruda, compared to Keytruda alone. This success has led to a strong reassessment of Moderna's future prospects, as the company aims to diversify beyond its COVID-19 vaccine business. The positive trial outcome and subsequent analyst upgrades are fueling investor optimism.

• 8/31/2026POSITIVE
  23 best-performing stocks of August, as the software industry continues its recovery

  Moderna Inc. emerged as the top-performing stock in August, significantly outperforming other companies within the energy and technology sectors. This exceptional performance highlights a strong recovery trend within the software industry, with Moderna leading the charge. Investors are likely to view this as a positive indicator of the company's resilience and growth potential, potentially attracting further investment and driving up its market valuation. The broader tech sector's recovery also bodes well for related companies.

• 8/27/2026NEUTRAL
  Moderna Capitalizes on Stock Jump With $2 Billion Note Offering

  Moderna Inc. announced plans to raise $2 billion through a convertible note offering. These notes can be exchanged for shares of the company's stock. The biotechnology firm intends to utilize the net proceeds for strategic investments in its cancer vaccine division and for the repayment of existing debt obligations. While the offering aims to fuel growth initiatives, the issuance of new debt, even if convertible, can introduce dilution concerns for existing shareholders and may not immediately translate into stock price appreciation.

• 8/27/2026NEGATIVE
  Moderna Capitalizes on Stock Jump With $2 Billion Offering

  Moderna Inc. announced plans to raise $2 billion through a convertible note offering. The company intends to use the proceeds for strategic investments in its cancer vaccine pipeline and to manage existing debt obligations. While the capital infusion could support future growth initiatives, the offering of notes convertible into shares dilutes existing shareholders' equity. This move, often seen as a sign of needing capital or a belief that the stock price is high enough to justify conversion, typically puts downward pressure on the stock price in the short term.